Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe

References

• Hutchings A, Schey C, Dutton R, et al. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020. Orphanet J Rare Dis 2014;9:22
   PubMed Web of Science ®Google Scholar
• Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin 2009;25:1285-93
   PubMed Web of Science ®Google Scholar
• Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011;6:42
   PubMed Web of Science ®Google Scholar
• McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? Br Med J 2005;331:1016-19
   PubMed Web of Science ®Google Scholar
• Williams S. The five most expensive drugs in the world. The Motley Fool. 2013. Available from: www.fool.com/investing/general/2013/06/29/the-5-most-expensive-drugs-in-the-world.aspx [Last accessed 21 June 2014]
   Google Scholar
• Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Value Health 2007;10(5):336-47
   PubMed Web of Science ®Google Scholar
• Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Orphanet J Rare Dis 2011;6:62
   PubMed Web of Science ®Google Scholar
• Kobayashi K, DeLab RJ. FDA review practices and priorities for drugs used in cancer treatment. Ann N Y Acad Sci 2001;949:341-4
   PubMed Web of Science ®Google Scholar
• Orphanet. Available from: www.orpha.net/ [Last accessed on 20 December 2013]
   Google Scholar
• Orphanet Report Series. Prevalence of rare diseases: bibliographic data. 2012. Available from: www.orpha.net
   Google Scholar
• EvaluatePharma. Orphan Drug Report. 2013
   Google Scholar
• Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis 2008;3:33
   PubMed Web of Science ®Google Scholar
• EU Competition Commission Pharmaceutical Sector Inquiry, Fact Sheet 1. Prices, time to generic entry and consumer savings. Available from: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/fact_sheet_1.pdf [Last accessed on 19 December 2013]
   Google Scholar
• Tambuyzer E. Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nature Rev Drug Dev 2010;9(12):921-9
   PubMed Web of Science ®Google Scholar
• Orfali M, Feldman L, Bhattachariee V, et al. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Clin Pharmacol Ther 2012;92(2):262-4
   PubMed Web of Science ®Google Scholar
• IMS Health Market Prognosis, June 2013. Available from: www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/Total_World_Pharma_Market_Topline_metrics_2012-17_regions.pdf [Last accessed on 30 January 2014]
   Google Scholar
• OECD. Health at a glance: Europe 2012, OECD Publishing. 2012. Available from: http://dx.doi.org/10.1787/9789264183896-en [Last accessed on 20 December 2013]
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR. 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014;17(1):5-14
   PubMed Web of Science ®Google Scholar
• European Commission. Guideline on aspects of the application of Article 8(1) and (3) of Regulation (EC) No 141/2000: Assessing similarity of medicinal products versus authorised orphan medicinal products benefiting from market exclusivity and applying derogations from that market exclusivity. Official Journal of the European Union. 2008
   Google Scholar
• Adang EM. Economic evaluation of innovative technologies in health care should include a short-run perspective. Eur J Health Econ 2008;9(4):381-4
   PubMed Web of Science ®Google Scholar
• A.D.A.M. Editorial Board. Familial lipoprotein lipase deficiency. In: Dugdale DC, Zieve D, editors. A.D.A.M. Medical Encyclopedia (National Center for Biotechnology Information). 2013
   Google Scholar
• Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis 2007;2:35
   PubMed Web of Science ®Google Scholar
• Genetics Home Reference. National Center for Biotechnology Information, Bethesda, Maryland, Available from: http://ghr.nlm.nih.gov/ [ Last accessed on 19 December 2013]
   Google Scholar
• Lobo C, Angulo IL, Aparicio LR, RELATH Investigators. Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload--the RELATH study. Hematology (Am Soc Hematol Educ Program) 2011;16(5):265-73
   Google Scholar
• Zimmerhackl LB, Besbas N, Jungraithmayr T, European Study Group for Haemolytic Uraemic Syndromes and Related Disorders. Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006;32(2):113-20
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Foundation. Cystic fibrosis foundation patient registry: annual data report 2011. Bethesda, MD: 2011
   Google Scholar
• Health Grades. Homozygous familial hypercholesterolemia. Available from: www.rightdiagnosis.com/h/homozygous_familial_hypercholesterolemia/basics.htm [Last accessed on 20 December 2013]
   Google Scholar
• Hoffman HM, Yasothan U, Kirkpatrick P. Fresh from the pipeline: rilonacept. Nat Rev Drug Discov 2008;7(5):385-6
   Web of Science ®Google Scholar
• Coelho T, Ericzon BG, Falk R, et al. A physician’s guide to transthyretin amyloidosis. 2008. Available from: www.amyloidosis.org/pdf/TTR%2008.pdf [Last accessed on 20 December 2013]
   Google Scholar
• Centers for Disease Control and Prevention. Anthrax (2009). Available from: www.cdc.gov/nczved/divisions/dfbmd/diseases/anthrax/technical.html [Last accessed on 20 December 2013]
   Google Scholar
• Fraser D. Hypophosphatasia. Am J Med 1957;22(5):730-46
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica 2006;91(4):460-6
   PubMed Web of Science ®Google Scholar
• Organ Procurement and Transplantation Network. Available from: http://optn.transplant.hrsa.gov/ [Last accessed on 3 January 2014]
   Google Scholar
• United States Renal Data System. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2011
   Google Scholar
• World Health Organization. GKT1 Activity and Practices. Available from: www.who.int/transplantation/gkt/statistics/en/index.html [Last accessed on 20 December 2013]
   Google Scholar
• Orens JB, Garrity ERJr. General overview of lung transplantation and review of organ allocation. Proc Am Thorac Soc 2009;6(1):13-19
   PubMedGoogle Scholar
• Hoofnagle JH, Carithers RLJr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995;21(1):240-52
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;20;281(3):249-54
   PubMed Web of Science ®Google Scholar